Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).

IF 5.1 2区医学 Q1 ONCOLOGY

Prostate Cancer and Prostatic Diseases Pub Date : 2024-10-01 DOI:10.1038/s41391-024-00901-4

Andrew J Armstrong, Amy Taylor, Michael C Haffner, Wassim Abida, Alan H Bryce, Lawrence I Karsh, Scott T Tagawa, Przemyslaw Twardowski, Anthony V Serritella, Joshua M Lang

{"title":"Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).","authors":"Andrew J Armstrong, Amy Taylor, Michael C Haffner, Wassim Abida, Alan H Bryce, Lawrence I Karsh, Scott T Tagawa, Przemyslaw Twardowski, Anthony V Serritella, Joshua M Lang","doi":"10.1038/s41391-024-00901-4","DOIUrl":null,"url":null,"abstract":"Background/objectives: Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer.Subjects/methods: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science.Results/conclusion: We argue for the widespread adoption of germline testing in all patients with prostate cancer and for somatic mutations testing in patients at the time of recurrent/metastatic disease. In this first part, we review how genomic testing is performed. We also review how to overcome certain barriers to integrate genetic and biomarker testing into clinical practice.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer and Prostatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41391-024-00901-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer.

Subjects/methods: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science.

Results/conclusion: We argue for the widespread adoption of germline testing in all patients with prostate cancer and for somatic mutations testing in patients at the time of recurrent/metastatic disease. In this first part, we review how genomic testing is performed. We also review how to overcome certain barriers to integrate genetic and biomarker testing into clinical practice.

查看原文本刊更多论文

前列腺癌患者同源修复缺陷的种系和体细胞检测（第 1 部分，共 2 部分）。

背景/目的：遗憾的是，并非所有转移性去势抵抗性前列腺癌（mCRPC）患者都能接受可延长生命的系统性疗法，这就强调了优化mCRPC治疗选择的必要性。有必要制定更好的指南来确定前列腺癌的基因检测：在这份由两部分组成、基于专家意见的指南中，我们就利用种系和体细胞检测来检测mCRPC患者的HRR改变提供了专家共识意见。本指南由2023-2024年召集的多学科专家小组制定，专家小组成员包括来自肿瘤内科、泌尿科、放射肿瘤科、病理科、医学基因组学和基础科学的代表：我们主张在所有前列腺癌患者中广泛采用种系检测，并在复发/转移性疾病患者中进行体细胞突变检测。在第一部分中，我们回顾了基因组检测是如何进行的。我们还回顾了如何克服某些障碍，将基因和生物标记物检测纳入临床实践。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate Cancer and Prostatic Diseases 医学-泌尿学与肾脏学

CiteScore

10.00

自引率

6.20%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management. Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis. Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.